Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Pre-sensitization of Malignant B Cells Through Venetoclax Significantly Improves the Cytotoxic Efficacy of CD19.CAR-T Cells
Mingya Yang, Lei Wang, Ming Ni, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 36

Showing 1-25 of 36 citing articles:

Born to survive: how cancer cells resist CAR T cell therapy
Jean Lemoine, Marco Ruella, Roch Houot
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 89
Modulation of BCL-2 in Both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T-cell Immunotherapy against Cancer
Yong Gu Lee, Puneeth Guruprasad, Guido Ghilardi, et al.
Cancer Discovery (2022) Vol. 12, Iss. 10, pp. 2372-2391
Open Access | Times Cited: 56
Advances in molecular targeted drugs in combination with CAR-T cell therapy for hematologic malignancies
Yuxian Huang, Yinjie Qin, Yingzhi He, et al.
Drug Resistance Updates (2024) Vol. 74, pp. 101082-101082
Open Access | Times Cited: 12
Challenges and Advances in Chimeric Antigen Receptor Therapy for Acute Myeloid Leukemia
Jennifer Marvin‐Peek, Bipin N. Savani, Olalekan O. Oluwole, et al.
Cancers (2022) Vol. 14, Iss. 3, pp. 497-497
Open Access | Times Cited: 30
Small-Molecule Compounds Boost CAR-T Cell Therapy in Hematological Malignancies
Xinping Cao, Xin Jin, Xiaomei Zhang, et al.
Current Treatment Options in Oncology (2023) Vol. 24, Iss. 3, pp. 184-211
Open Access | Times Cited: 16
Overcoming the challenges of primary resistance and relapse after CAR-T cell therapy
Alexandra Dreyzin, Alexander W. Rankin, Katia Luciani, et al.
Expert Review of Clinical Immunology (2024) Vol. 20, Iss. 7, pp. 745-763
Closed Access | Times Cited: 6
Apoptosis: aJanus bifronsin T-cell immunotherapy
Yong Gu Lee, Nicholas Yang, Inkook Chun, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 4, pp. e005967-e005967
Open Access | Times Cited: 13
BCL-2 dependence is a favorable predictive marker of response to therapy for chronic lymphocytic leukemia
Stephen Jun Fei Chong, Junyan Lu, Rebecca Valentin, et al.
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access
Combination strategies to optimize the efficacy of chimeric antigen receptor T cell therapy in haematological malignancies
Xinyi Xiao, Yazhuo Wang, Zhengbang Zou, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 22
Relapsed/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors
Madelyn Burkart, Reem Karmali
Journal of Personalized Medicine (2022) Vol. 12, Iss. 3, pp. 376-376
Open Access | Times Cited: 20
Enhanced Chimeric Antigen Receptor T Cell Therapy through Co-Application of Synergistic Combination Partners
Sophia Stock, Anna-Kristina Kluever, Stefan Endres, et al.
Biomedicines (2022) Vol. 10, Iss. 2, pp. 307-307
Open Access | Times Cited: 19
How We Incorporate Venetoclax in Treatment Regimens for Acute Myeloid Leukemia
Abhishek Maiti, Marina Konopleva
The Cancer Journal (2022) Vol. 28, Iss. 1, pp. 2-13
Open Access | Times Cited: 19
Multi-Targeting CAR-T Cell Strategies to Overcome Immune Evasion in Lymphoid and Myeloid Malignancies
Jessica Peter, Fabio Toppeta, Alexandre Trubert, et al.
Oncology Research and Treatment (2025), pp. 1-15
Closed Access
BH3 mimetics augment cytotoxic T cell killing of acute myeloid leukemia via mitochondrial apoptotic mechanism
Kapil Saxena, Shao-Hsi Hung, Esther Ryu, et al.
Cell Death Discovery (2025) Vol. 11, Iss. 1
Open Access
The BCL-2 Inhibitor Venetoclax Augments Immune Effector Function Mediated by Fas Ligand, TRAIL, and Perforin/Granzyme B, Resulting in Reduced Plasma Viremia and Decreased HIV Reservoir Size during Acute HIV Infection in a Humanized Mouse Model
Aswath P. Chandrasekar, Nathan W. Cummins, Sekar Natesampillai, et al.
Journal of Virology (2022) Vol. 96, Iss. 24
Open Access | Times Cited: 16
Beyond Bruton’s tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody–drug conjugates, CAR T-cells, and novel agents
Neeraj Jain, Mukesh Mamgain, Sayan Mullick Chowdhury, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 10
Transcriptome Characterization of Short Distance Transport Stress in Beef Cattle Blood
Haidong Zhao, Xiaoqin Tang, Mingli Wu, et al.
Frontiers in Genetics (2021) Vol. 12
Open Access | Times Cited: 21
Pediatric multicellular tumor spheroid models illustrate a therapeutic potential by combining BH3 mimetics with Natural Killer (NK) cell-based immunotherapy
Vinzenz Särchen, Senthan Shanmugalingam, Sarah Kehr, et al.
Cell Death Discovery (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 14
CARs and Drugs: Pharmacological Ways of Boosting CAR-T-Cell Therapy
Dennis Christoph Harrer, Jan Dörrie, Niels Schaft
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2342-2342
Open Access | Times Cited: 8
Strategies for Reducing Toxicity and Enhancing Efficacy of Chimeric Antigen Receptor T Cell Therapy in Hematological Malignancies
Haobing Wang, Ling Tang, Yingjie Kong, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 11, pp. 9115-9115
Open Access | Times Cited: 8
Prime, shock and kill: BCL-2 inhibition for HIV cure
Aswath P. Chandrasekar, Andrew D. Badley
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 13
Conventional Therapeutics in BPDCN Patients—Do They Still Have a Place in the Era of Targeted Therapies?
Margaux Poussard, Fanny Angelot‐Delettre, Éric Deconinck
Cancers (2022) Vol. 14, Iss. 15, pp. 3767-3767
Open Access | Times Cited: 12
Venetoclax enhances the efficacy of therapeutic antibodies in B-cell malignancies by augmenting tumor cell phagocytosis
Fotini Vogiatzi, Julia Heymann, Kristina Müller, et al.
Blood Advances (2022) Vol. 6, Iss. 16, pp. 4847-4858
Open Access | Times Cited: 10
Recent advances in genomics and therapeutics in mantle cell lymphoma
Tingxun Lu, Jie Zhang, Jenna McCracken, et al.
Cancer Treatment Reviews (2023) Vol. 122, pp. 102651-102651
Closed Access | Times Cited: 4
HDAC Inhibition for Optimized Cellular Immunotherapy of NY-ESO-1-Positive Soft Tissue Sarcoma
Wenjie Gong, Lei Wang, Maria‐Luisa Schubert, et al.
Biomedicines (2022) Vol. 10, Iss. 2, pp. 373-373
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top